Pharmaceutical Solid Forms Balancing Stability and Bioavailability

The patent applies parameter changes by systematically varying physical and chemical parameters during solid form development, including solvent selection, temperature profiles, pH conditions, and crystallization rates. This methodical parameter optimization enables reliable identification and preparation of specific solid forms (crystalline polymorphs, amorphous forms, solvates) that enhance drug solubility and bioavailability while reducing the unpredictability of the process

The patent employs preliminary action through extensive preliminary screening and characterization studies to identify promising solid forms before final formulation development. This includes preliminary thermal analysis, X-ray diffraction studies, and solubility assessments that guide subsequent preparation processes, thereby reducing overall complexity and improving reliability of therapeutic outcomes

The patent applies composite materials by creating composite solid forms that combine crystalline regions with amorphous regions, or by forming co-crystals and solvates that integrate the active pharmaceutical ingredient with suitable co-formers. These composite structures provide both the physical and chemical stability of crystalline forms and the enhanced dissolution characteristics of amorphous regions, thereby simultaneously improving stability and bioavailability

The patent utilizes another dimension by transitioning between different solid state dimensions and configurations - from fully crystalline to partially amorphous to amorphous-dispersed-in-polymer systems. This dimensional flexibility allows optimization of both stability and dissolution properties by selecting the appropriate degree of molecular order and spatial arrangement for each specific formulation requirement

The patent applies flexible shells and thin films by dispersing amorphous pharmaceutical compounds within polymer matrices or coating layers that physically constrain the amorphous material. This approach maintains the enhanced dissolution profile of amorphous forms while the polymer matrix provides physical stability and prevents unwanted phase transitions or crystallization during storage and handling

The patent uses intermediaries by introducing stabilizing agents, surfactants, or excipients that act as mediators between the amorphous pharmaceutical compound and the environment. These intermediary substances protect the amorphous form from physical degradation, reduce molecular mobility, and maintain structural integrity during storage, thereby improving physical stability without compromising the dissolution enhancement benefits